Effects of a price cut reform on the cost and utilization of antidiabetic drugs in Korea: a national health insurance database study

Hae Sun Suh¹, Jee-Ae Kim² and Iyn-Hyang Lee³*

Abstract

Background: Despite the potential widespread application and a significant need, the policy effectiveness of prescribed medications price controls has not been studied extensively. We aimed to explore the effects of a price cut introduced in April 1st of 2012 on the cost and utilization of antidiabetics in South Korea.

Methods: We identified approximately four million outpatients who filed at least one diabetes-related claim during the index period (January 2010 to December 2012) using the National Health Insurance claims data. We performed interrupted time series analyses for cost and utilization of “overall,” “reduced price,” and “constant price” antidiabetics between January 2009 and June 2013, and measured the growth rate for incidents of medical and surgical procedures for diabetes-induced complications.

Results: The segmented regression suggests that spending on overall and reduced price antidiabetics would drop by 6 and 23%, respectively; spending on constant price antidiabetics would rise by 16% in a year after the new pricing compared to if the policy were not in existence. There were a few immediate changes in utilization, and its trend indicated a significant decrease in reduced price antidiabetics and an increase in constant price antidiabetics. Incidents of medical and surgical procedures relating to diabetic complications were unaffected.

Conclusions: The Korean price cut program contained costs by immediately reducing the cost of pharmaceuticals without any major signals associated with compromised clinical conditions in diabetic patients.

Keywords: Direct price control, Price cut, Pharmaceutical costs, Pharmaceutical utilization, Antidiabetics

Background

In many countries, healthcare authorities face challenges in containing expenditure on pharmaceuticals [1–4]. Governments are exploring more cost-effective strategies in regulating pharmaceuticals in a world of finite resources [5]. On the other hand, the “growing need for evidence-based healthcare” is leading to an increased demand for evidence that demonstrates the value of policies to governments [6–8]. In order to meet such societal goals, drug policies continue to evolve and are becoming increasingly complex [2, 9–13].

Along with cost-sharing schedules, price control policies are one of the most conventional strategies in drug policies [12, 14]. There is abundant evidence available for cost-sharing policies compared to price control strategies. Cost-sharing schemes have reduced drug expenditure by controlling public demand for pharmaceuticals [10, 15, 16]. However, obviously, excessive suppression of pharmaceutical use results in unwanted consequences in vulnerable populations (e.g., elderly, low income households). Reported consequences include an increase in institutionalization [17], emergency room visits [18], and physician visits [19], which imply the exacerbation of patient conditions and a decline in using essential medications [20], leading patients to suffer from more serious conditions.

Contrary to cost-sharing schemes, price control strategies work on the supply side of the pharmaceutical market, and as such, the pharmaceutical industry is the main stakeholder affected [13, 21]. Under price control strategies, governments set price limits, profit limits, and...
mark-up limits to restrain the industry from exploiting their monopolistic position in pricing [14]. Authorities in countries such as the United Kingdom, United States, France, and Italy negotiate pharmaceutical prices with the industry through strategies like price-volume agreements or risk-sharing schemes [22, 23]. At a national level, the United States is a unique market that allows the industry to set their price based primarily on the principle of market competition.

Guillen and Cabiedes [1] argued that the industry seemed to be extremely successful in seeking “escape valves” by selling more products and/or selling premium products. Thus, it is crucial to study how pricing policies work [24]. Despite the potential widespread application and a significant need, the policy effectiveness of price controls has not been studied extensively. Pertinent policy studies are surprisingly limited and existing evidence is mainly around how reference pricing works [15, 25, 26]. Lee et al. [15] systematically reviewed studies on pharmaceutical policies over the past 30 years and found 25 studies that examined price controls using robust scientific methods. Of those, sixteen studies explored reference pricing programs and only nine studies explored other types of pricing programs. Of the nine studies, a single study from Ireland reported significant savings in expenditure after a reduction in the wholesale margin. Cochrane’s updated review only found two policy studies on maximum prices or index pricing and concluded uncertainty in the effect of pricing policies “due to sparse evidence” [26].

The purpose of this study is to explore the impact of a direct price cut on pharmaceutical costs, utilization, and any consequences that possibly compromised the public health in South Korea, where a price cut schedule was implemented in April 2012. With this new policy, the Korean government aimed to contain pharmaceutical costs with few changes in the patients’ utilization of pharmaceuticals, and thus, without compromising public health. The price cut was also expected to improve health disparities by lowering the price of medications which became more affordable to those at the margins of society with limited ability to access medications. Our study focuses on antidiabetics, which is a medication used for diabetes, a chronic disease, and examines the impacts of the policy for over one year after policy implementation.

Methods
Policy intervention and study design
Since 2006, Korea has had a drug pricing system in which the prices for original pharmaceuticals declines to 80% of the on-patent prices when the patent expires. Prices for generics were set to 90% of off-patent prices and varied depending on when they entered the market; the earlier they entered, the higher the price. In April 1st of 2012, the government introduced a new pricing system, known as the “Single Price System (SPS).” Prices for off-patents were reduced from 80 to 70% of the on-patent prices, and generics were uniformly priced at 85% of their off-patent counterparts (equivalent to 59.5% of the on-patent price). One year after the expiration of patents, all pharmaceuticals including off-patents and their generics were priced at 53.55% of the on-patent prices [27]. We used an interrupted time series design to test the impact of the SPS on the cost and utilization of antidiabetics. We built a time series for each of the outcome variables over 54 months (4.5 years) between January 2009 and June 2013. The intervention policy occurred at the 40th month, and there were 15 months in the post-intervention period.

Data source and population
We examined the administrative National Health Insurance (NHI) claims databases of the Health Insurance Review & Assessment Service (HIRA) to identify the study population. The Korean healthcare system is composed of a mandatory social insurance plan, the NHI, and a medical aid program (Medical Aid, MedAid) that provides additional benefits to low income households. Since 2000, the two national health plans have covered the entire population—about 97% by the NHI and 3% by MedAid [28]. Since Korea has a mandatory health security system for national health insurance, the NHI claims that the database contains all medical and prescription drug claims records for the entire population in Korea.

Subjects for this study are adult beneficiaries (≥20 years old) covered by either NHI or MedAid who had at least one claim with the diagnosis of diabetes mellitus in an outpatient setting during the reference period between January 1, 2010 and December 31, 2012. The subject included in the study were cases with Type 2 Diabetes Mellitus as diagnosis using the codes of E11 (non-insulin-dependent diabetes mellitus) or E14 (unspecified diabetes mellitus excluding insulin-dependent diabetes mellitus, etc.) in the 6th Korean Standard Classification of Diseases and Causes of Death, an official Korean version of the 10th version of the International Classification of Diseases (ICD-10) [29]. After specifying the study population, we established a dataset composed of the study subjects’ medical and drug claims between January 1, 2009 and June 31, 2013.

Identification and classification of antidiabetics
We defined antidiabetics as medications in the WHO Anatomic Therapeutic Chemical (ATC) group A10. To identify A10 medications from the claims, we used the Korean National Drug Classification system and searched for the drug group “396” which corresponds to the ATC group A10 [30]. We identified 104 insurance codes of active ingredients for antidiabetics from the Korean
drug benefits list and finally included 97 codes by eliminating seven which were deleted before January 2008 from the benefit list. Of those, we found 32 ingredients that had their prices cut by the SPS in April 2012 and grouped these as “antidiabetics with reduced price (antidiabetics\textsubscript{p-cut}).” The rest of the antidiabetics were grouped as “antidiabetics with constant price (antidiabetics\textsubscript{p-keep}).”

**Outcome measures**

*Primary outcomes* were the monthly cost and utilization of antidiabetics after the price cut. *Secondary outcomes* were individual cost, utilization of antidiabetics, and incidents of medical and surgical procedures for diabetic complications in the study sample. Each measure was operationally defined as in Table 1.

**Statistical analysis**

We present descriptive statistics for all variables. We measured annual growth rates in incidents of medical and surgical procedures relating to diabetic complications, including diabetic retinopathy, diabetic cataract, diabetic nephropathy, cardiovascular complications, and diabetic foot lesions. We examined the time-series data of interests graphically and established segmented regression models to assess statistical significance of the policy effects. We measured policy effects as a change in the slope and level of the time series [31]. In the time series analysis, any change in the slope indicates a long term effect of the policy, and any change in the level stands for an abrupt effect of the policy. We used the Durbin–Watson test to assess serial correlation and estimated the regression coefficients with either an ordinary least squares (OLS) or a first order autocorrelation maximum likelihood estimate (AR) depending on the significance of serial correlations [32]. Using the SAS autoregression procedure, outcome variables were analyzed by time series methods. The final model for each time series was selected based on the minimum Akaike Information Criterion score [33]. We carried out residual analyses based on autocorrelation plots and partial autocorrelation plots. Assessed models were chosen from those that resulted in residuals that were not significantly different from white noise.

Through repeated model specifications, we were able to build the final model for the time series of interest as below.

\[
Y_t = \beta_0 + \beta_1 \cdot \text{time}_t + \beta_2 \cdot \text{OPIP}_t \\
+ \beta_3 \cdot \text{time after OPIP}_t + \beta_4 \cdot \text{SPS}_t \\
+ \beta_5 \cdot \text{time after SPS}_t + \beta_6 \cdot \text{Feb} + \varepsilon_t
\]

Where \( Y_t \) is the outcome variable (as defined in “Outcome measures”) in month \( t \); time is a continuous variable

| Table 1 Definition of outcome measures |
|--------------------------------------|
| **Outcomes** | **Measures** | **Definition** |
| Primary outcomes | Pharmaceutical cost* (total) | • Monthly cost of antidiabetics |
| | Pharmaceutical utilization (total) | • Monthly DDDs of antidiabetics |
| | | • Monthly number of patients with at least one antidiabetics |
| Secondary outcomes | Pharmaceutical cost* (per patient) | • Monthly cost per patient with antidiabetics |
| | Pharmaceutical utilization (per patient) | • Monthly DDDs per patient with antidiabetics |
| | Incidents of medical and surgical procedures relating to diabetic complications | • Diabetic retinopathy including 3 procedures (panretinal photocoagulation, and vitrectomy) |
| | | • Diabetic cataract including 4 procedures (extracapsular or intracapsular extraction, pars plana lensectomy, phacoemulsification, and surgery after cataract) |
| | | • Diabetic nephropathy including 20 procedures (e.g., AV shunt, fistula formation or various intravenous catheter insertions for hemodialysis, kidney transplant) |
| | | • Cardiovascular complications of diabetics including 15 procedures (e.g., percutaneous coronary intervention, coronary artery bypass grafting) |
| | | • Diabetic foot lesions including 31 procedures (e.g., limb amputation, atherectomy) |

*Cost in Korean won, KRW (1 US dollar \( \approx 1000 \) KRW); DDD = defined daily dose (In the case of pharmaceutical items without DDD information, for example, combinations of oral blood glucose lowering drugs (A10BD), we divided the total quantity consumed by the standard daily dosage designated for adults in the Korean official labels to compute total DDDs for that item)
indicating time in months from January 2009 to June 2013; OPIP is a dummy variable for time \( t \) occurring before (policy = 0) or after (policy = 1) the launch of the Outpatient Prescription Incentive Program (OPIP, October 2010); time after OPIP is a continuous variable coded 0 before the launch of the OPIP, and then counted 1 in October 2010 to 33 in June 2013; SPS is a dummy variable for time \( t \) occurring before (price cut = 0) or after (price cut = 1) the launch of the SPS scheme (April 2012); time after SPS is a continuous variable coded 0 before the launch of the SPS, and then counted 1 in April 2012 to 15 in June 2013; and Feb is a dummy variable indicating the month of February in each year (February = 1, other months = 0).

In the model, \( \beta_0 \) estimates the baseline levels of the outcome variables; \( \beta_1 \) estimates the changes in the outcome variables before the OPIP, i.e. the baseline trends; \( \beta_2 \) estimates the level changes in the outcome variables after the OPIP; \( \beta_3 \) estimates the changes in the trend of the outcome variables after the OPIP; \( \beta_4 \) estimates the level changes in the outcome variables after the SPS; \( \beta_5 \) estimates the changes in the trend of the outcome variables after the SPS and \( \beta_6 \) is a coefficient for the February variable.

The OPIP variables represent the Outpatient Prescription Incentive Program (OPIP), a policy introduced in October 2010 during the study period. The OPIP is an incentive program for prescribers who have achieved savings in their pharmaceutical expenditure compared to the year before [34]. This variable was introduced for covariate control since there is a possibility of its influence on pharmaceutical costs through changing prescribing behavior. The February variable is a dummy variable indicating whether the data is from February of each year. February has less days than other months so pharmaceutical utilization was observed to be low, and thus there was a need to control its influence on the estimation. We performed the analyses in SAS 9.4 (SAS Institute Inc., Cary, NC, USA). We determined statistical significance at \( p \leq 0.05 \).

**Results**

**Study population demographics and descriptive summary of the data**

Table 2 gives an overview of the study population. Approximately four million beneficiaries were identified as being diagnosed with diabetes mellitus, and had at least one claim during the index period. The study cohort was comprised of 53–54% women and 92% National Health Insurance beneficiaries (8% Medical Aid). The mean age of the cohort changed from 60 in 2009 to 62 in 2012. Total healthcare cost increased from 682 billion KRW in 2009 to 952 billion KRW in 2012. Total patient copayments grew from 51 billion KRW in 2009 to 55 billion KRW in 2010, and dropped by 10% to 50.5 billion KRW in 2012 after the introduction of the SPS scheme. While the quantity of

| Table 2 | Population demographics and descriptive summary of data |
|---------|-----------------------------------------------|
|         | 2009 April 2009 to March 2010 | 2010 April 2010 to March 2011 | 2011 April 2011 to March 2012 | 2012 April 2012 to March 2013 |
| Beneficiaries, monthly mean ± SD | 3,878,295 ± 80,558 | 4,013,070 ± 75,172 | 4,074,566 ± 47,546 | 4,050,415 ± 52,953 |
| Men, % | 46.1 | 46.6 | 46.9 | 47.1 |
| Women, % | 53.9 | 53.4 | 53.1 | 52.9 |
| Age, mean ± SD | 60.11 ± 12.93 | 60.72 ± 12.98 | 61.30 ± 12.95 | 61.95 ± 12.86 |
| Medical Aid beneficiaries, % | 8.03 | 8.12 | 7.96 | 7.73 |
| Total healthcare costs, monthly mean ± SD (billion KRW) | 681.80 ± 74.15 | 844.85 ± 53.19 | 924.49 ± 47.72 | 952.44 ± 54.81 |
| Total copayments, monthly mean ± SD (billion KRW) | 51.13 ± 2.71 | 55.07 ± 2.43 | 54.49 ± 2.43 | 50.50 ± 2.13 |
| Total drug costs, outpatients, monthly mean ± SD (billion KRW) | 290.28 ± 15.16 | 312.74 ± 15.97 | 327.62 ± 7.56 | 292.91 ± 8.55 |
| Costs of antidiabetics, outpatients, monthly mean ± SD (billion KRW) | 32.77 ± 1.78 | 35.30 ± 1.68 | 36.89 ± 0.86 | 35.75 ± 1.55 |
| Costs in price reduced group | 24.21 ± 1.01 | 25.28 ± 1.25 | 24.82 ± 0.97 | 18.44 ± 0.79 |
| Costs in price constant group | 8.56 ± 1.02 | 10.02 ± 0.57 | 12.07 ± 1.24 | 17.31 ± 1.85 |
| DDDs of antidiabetics, monthly mean ± SD (million) | 83.56 ± 4.22 | 88.53 ± 4.34 | 93.39 ± 2.15 | 97.12 ± 2.64 |
| DDDs in price reduced group | 71.75 ± 2.94 | 74.16 ± 3.56 | 75.39 ± 1.42 | 72.38 ± 2.27 |
| DDDs in price constant group | 11.81 ± 1.70 | 14.37 ± 0.86 | 18.00 ± 1.70 | 24.74 ± 2.27 |
| Number of prescriptions with antidiabetics, monthly mean ± SD | 1,520,685 ± 58,707 | 1,632,339 ± 57,761 | 1,762,863 ± 56,913 | 1,935,612 ± 58,314 |
| Number of prescriptions in price reduced group | 1,174,390 ± 34,270 | 1,226,601 ± 41,480 | 1,286,483 ± 22,929 | 1,316,360 ± 25,313 |
| Number of prescriptions in price constant group | 346,295 ± 27,689 | 405,739 ± 17,125 | 476,380 ± 36,017 | 619,221 ± 48,936 |

SD standard deviation, KRW Korean won (1000 KRW ≒ 1 US$ in January 2015), DDD defined daily dose
antidiabetics prescribed increased from 84 to 97 million DDDs (Defined Daily Doses) during the study period, the cost spent on antidiabetics took a downturn from 37 to 36 billion KRW between 2011 and 2012 with the introduction of the SPS scheme.

**Effects on the cost of antidiabetics**

During the baseline period until the SPS, monthly average spending on antidiabetics$_{\text{p-cut}}$ was stable at 24–25 billion KRW, but dropped by 28% to 18 billion KRW after the scheme (Table 2). In the regression model, a 4.8 billion KRW drop in level ($p < 0.001$) and a 0.02 billion KRW insignificantly reduced by 4.4 billion KRW in the month that the policy was implemented ($\beta_2 = 0.211, p < 0.001$, Table 3).

In contrast, spending on antidiabetics$_{\text{p-keep}}$ rose steeply by 42% from 12 to 17 billion KRW per month during the year after the SPS scheme, compared to a 19–20% increase during the baseline period (Table 2). A slope for the time series of antidiabetics$_{\text{p-keep}}$ costs was increased from 0.28 to 0.49 billion KRW per month after the scheme was implemented ($\beta_3 = 0.121, p < 0.05$, Table 3).

Collectively, the overall cost of antidiabetics was immediately reduced by 4.4 billion KRW in the month that the new pricing began, but showed a rising trend from 0.16 to 0.35 billion KRW per month afterwards (both $p < 0.01$, Table 3).

Figure 1 shows the outcome measures for (a) cost of overall antidiabetics, (b) cost of antidiabetics with reduced prices (antidiabetics$_{\text{p-cut}}$), and (c) cost of antidiabetics with constant prices (antidiabetics$_{\text{p-keep}}$) along with each of the forecasted series with 95% confidence intervals. The segmented regression models suggest that the cost spent on overall antidiabetics and antidiabetics$_{\text{p-cut}}$ would drop by 6 and 23%, respectively, in a year after the new pricing, compared to if the policy were not in existence. At the end point of the data period (the 15th month after the introduction of the policy), the rate of the decline was larger; 9% for overall antidiabetics (monthly average = 7%) and 27% for antidiabetics$_{\text{p-cut}}$ (monthly average = 21%). In contrast, cost of antidiabetics$_{\text{p-keep}}$ would rise by 16% in a year after the new pricing, compared to if the policy were not in existence. The rate of growth faded to 13% at the 15th month after the new pricing (monthly average = 13%).

**Effects on the utilization of antidiabetics**

Overall antidiabetic use was not significantly affected by the price cut, but changes seen in antidiabetics$_{\text{p-cut}}$ and

| Table 3 Segmented regression coefficients for antidiabetics in outpatients by the price cut |
|-----------------------------------------------|------------------|----------------------|-----------------|-----------------|-----------------|-----------------|---------------|
| Outcome variable | Policy group | Model | Coefficient | Baseline | Outpatient Prescription (OPP) | Price cut (SPS) | February | AR(1) | DW |
|------------------|--------------|-------|-------------|----------|-----------------------------|-----------------|----------|-------|-----|
| Costs (KRW)     | Overall      | AR    | $\beta_0$ | 29.982  | 0.295            | -0.984           | -0.136        | 4.384           | 0.192          | -2.643          | 0.282           | 1.98            |
|                  | Reduced      | AR    | $\beta_2$ | 25.738  | 0.065            | 1.357           | -0.185         | -4.809          | -0.023         | -1.858          | 0.277           | 2.06            |
|                  | Constant     | AR    | $\beta_3$ | 6.240   | 0.229            | -2.264          | 0.049          | 0.384           | 0.211          | -0.856          | -0.080          | 1.80            |
|                  | Overall      | AR    | $\beta_4$ | 79.447  | 0.463            | -0.556          | -0.023         | -1.058          | -0.114         | -6.344          | 0.338           | 2.12            |
|                  | Reduced      | AR    | $\beta_5$ | 70.638  | 0.161            | 1.321           | -0.119         | -1.442          | -0.340         | -5.002          | 0.333           | 2.14            |
|                  | Constant     | AR    | $\beta_6$ | 8.794   | 0.301            | -1.792          | 0.094          | 0.426           | 0.220          | -1.370          | -       | 1.99            |
|                  | Overall      | OLS   | $\beta_7$ | 1.408   | 11.758           | -47643          | 1698             | 17.535          | -2504          | -89,533         | -       | 1.95            |
|                  | Reduced      | OLS   | $\beta_8$ | 1.129   | 4909            | -6604           | 532             | 7296            | -7523          | -64,306          | -       | 2.07            |
|                  | Constant     | OLS   | $\beta_9$ | 278.489 | 6820           | -39,690         | 1207            | 8751            | 4989          | -26,186         | -0.168          | 1.79            |
| Costs per patient (KRW) | Overall      | OLS   | $\beta_0$ | 43.492  | 160            | -2149           | -163           | -3380          | 107            | -1063          | -       | 1.86            |
|                  | Reduced      | OLS   | $\beta_2$ | 20.992  | -30           | 1123            | -145           | -3670          | 81            | -550            | -       | 1.96            |
|                  | Constant     | OLS   | $\beta_3$ | 22.455  | 183           | -2800           | -27            | 233             | 43            | -499          | -0.485           | 2.12            |
| DDDs per patient | Overall      | AR    | $\beta_4$ | 94.160  | 0.095            | 0.317           | -0.083         | -1.564          | -0.010         | -2.610          | 0.224           | 2.12            |
|                  | Reduced      | AR    | $\beta_5$ | 62.535  | -0.120          | 1.330           | -0.009         | -1.416          | 0.056         | -1.384          | 0.135           | 2.04            |
|                  | Constant     | AR    | $\beta_6$ | 31.594  | 0.215            | -0.934          | -0.0004        | 0.005           | -0.068         | -1.123          | -       | 2.08            |

$\beta_0 =$ coefficients for the baseline levels of the outcome variables; $\beta_1 =$ coefficients for the changes in the outcome variables before the OPP, i.e. the baseline trends; $\beta_2 =$ coefficients for the level changes in the outcome variables after the OPP; $\beta_3 =$ coefficients for the changes in the trend of the outcome variables after the OPP; $\beta_4 =$ coefficients for the level changes in the outcome variables after the SPS; $\beta_5 =$ coefficients for the changes in the trend of the outcome variables after the SPS; $\beta_6 =$ coefficients for Feb variables

OLS ordinary least squares estimates, AR 1st order Autocorrelation Maximum likelihood estimates, DW Durbin-Watson d statistic, KRW Korean won (1000 KRW = 1 US$ in January 2015), DDD defined dose
d$f$ $p < 0.1; \dagger p < 0.05; \ddagger p < 0.01; \dagger \dagger p < 0.001$
Fig. 1 Observed and forecasted costs of antidiabetics. 

- **a** Overall antidiabetics
- **b** Antidiabetics with reduced price
- **c** Antidiabetics with constant price

Gray band = 95% confidence interval; * real values; — observed trend; ——— forecasted trend. KRW = Korean won (1000 KRW ≈ 1 US dollar)

Suh et al. BMC Health Services Research (2018) 18:429
antidiabetics\textsubscript{p-keep} were the opposite. After the scheme was introduced, the increasing trends in the time series of antidiabetics\textsubscript{p-cut} was reversed from 0.042 to −0.298 million DDDs per month ($\beta_5 = -0.340$, $p < 0.01$; Table 3), and the increasing trends of the time series of antidiabetics\textsubscript{p-keep} increased from 0.395 to 0.615 million DDDs per month ($\beta_5 = 0.220$, $p < 0.001$; Table 3). The slope of the time series of the number of patients prescribed antidiabetics\textsubscript{p-cut} was overturned from 5441 to −2082 persons per month after the introduction of the scheme ($\beta_5 = -7523$, $p < 0.001$; Table 3). The slope of the number of patients in antidiabetics\textsubscript{p-keep} increased from 8027 to 13,016 persons per month ($\beta_5 = 4989$, $p < 0.001$; Table 3).

The segmented regression model suggests that the DDD utilization of overall antidiabetics and antidiabetics\textsubscript{p-cut} would drop by 3 and 8% respectively in a year after the new pricing, compared to if the policy were not in existence. At the end point of the data period (the 15th month after the introduction of the policy), the rate of decline was larger; 8% for overall antidiabetics and 14% for antidiabetics\textsubscript{p-cut}. The segmented regression model suggests that the utilization of antidiabetics\textsubscript{p-keep} would rise by 12% in a year after the new pricing, compared to if the policy were not in existence (monthly average = 2 and 5% respectively). The growth faded to 8% at the 15th month after the new pricing (monthly average = 9%).

**Effects on the cost and use of individual patients**

After the SPS scheme, cost per patient for overall antidiabetics and antidiabetics\textsubscript{p-cut} showed a significant and immediate reduction by 3380 and 3670 KRW, respectively (both $p < 0.001$). Cost per patient for overall antidiabetics switched to an increasing trend from −2.1 to 104.8 KRW per month. The decreasing rate of cost per patient for antidiabetics\textsubscript{p-cut} slowed down from −174.8 to −94.1 KRW per month. The changes per patient cost of antidiabetics\textsubscript{p-keep} were found to be insignificant both in the level and the slope ($p > 0.1$; Table 3).

On a per patient basis, a 1.4 DDD drop was seen in antidiabetics\textsubscript{p-cut} in the month when the new pricing was introduced ($p < 0.05$; Table 3). Besides this, no major changes were observed in the slope for the individual use of antidiabetics\textsubscript{p-cut} or in the level and slope of overall antidiabetics or antidiabetics\textsubscript{p-keep} ($p > 0.1$; Table 3).

**Incidents of medical and surgical procedures relating to diabetic complications**

Table 4 displays the changes in monthly incidents of diabetes-induced medical and surgical procedures during the study period. The annual growth rate after the new pricing were 3–7% lower than those in the baseline period in all procedures that were examined.

**Discussion**

The Korean government introduced the SPS, a direct price cut schedule in pharmaceutical pricing to contain pharmaceutical expenditure without causing any major negative changes in public health. Through analyzing the claims data, we found that a direct price cut contained costs during the study period by bringing an immediate cost reduction in the targeted pharmaceuticals. Additionally, we discovered that incidents of medical and surgical procedures relating to diabetic complications were unaffected or marginally reduced, suggesting the absence of any major effects on individual clinical outcomes during the study period. As individual utilization was only affected momentarily when the price of pharmaceuticals was reduced by the pricing policy, we cautiously expect few consequences in the long run, beyond the study period.

The savings was, however, expected to be offset by a prescription shift from reduced price pharmaceuticals (targeted) to constant price pharmaceuticals (non-targeted) in the long run. This was because antidiabetics with constant prices mostly included on-patent products with higher prices than the targeted antidiabetics, or new pharmaceutical entities uninfluenced by the new pricing policy. Similar phenomena had been observed in the case of antihyperlipidemic agents in Korea [35]. Extensive price cuts between 2008 and 2010 did not effectively contain the growth of pharmaceutical expenditures due to several factors, including the increased use of expensive drugs. Antihyperlipidemic agents without the

| Table 4 Monthly incidents of medical and surgical procedures relating to diabetic complications in the study cohort |
|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
|                 | 2009 April 2009 to March 2010 | 2010 April 2010 to March 2011 | 2011 April 2011 to March 2012 | 2012 April 2012 to March 2013 |
|                 | Episodes per 1000 patients | Episodes per 1000 patients | Annual growth (%) | Episodes per 1000 patients | Annual growth (%) | Episodes per 1000 patients | Annual growth (%) |
| diabetic retinopathy, monthly | 0.27 | 0.29 | +0.02 (7%) | 0.30 | +0.01 (3%) | 0.30 | 0.0 (0%) |
| diabetic cataract, monthly | 1.98 | 2.08 | +0.1 (5%) | 2.19 | +0.11 (5%) | 2.23 | +0.04 (2%) |
| diabetic nephropathy, monthly | 0.47 | 0.67 | +0.2 (43%) | 0.74 | +0.07 (10%) | 0.75 | +0.01 (1%) |
| cardiovascular complications of diabetics, monthly | 2.49 | 2.84 | +0.35 (14%) | 2.90 | +0.06 (2%) | 2.76 | −0.14 (−5%) |
| diabetic foot lesions, monthly | 0.40 | 0.53 | +0.13 (33%) | 0.62 | +0.09 (17%) | 0.68 | +0.06 (10%) |
price cuts showed increased expenditure and volume trends, which was also observed in antidiabetic agents in our analysis. Han et al. [36] also found that the price cut in antibiotics reduced pharmaceutical expenditures immediately, but the effect faded over the long run. Another study found that the price cut policy decreased expenditures of antihypertensive drugs, though the effect faded out over time [37]. The authors suggested that this might be because clinicians switched to pharmaceuticals with a constant price, which led to an unintended impact of increased drug utilization. The phenomenon of prescription shift from targeted to non-targeted products was in line with the results reported by Hsu et al. [38]. A shift of expenditure and utilization from “targeted” to “non-targeted” oral antidiabetics was seen after a reduction in drug reimbursement in Taiwan.

Rationally, few economic motivations exist for prescribers or dispensers to move from pharmaceuticals with reduced prices to those with constant prices in Korea. This is because the Korean government has not allowed any mark-up profits for healthcare providers in prescription pharmaceuticals since 1999, and healthcare providers have been rewarded only through service fees [27]. Pharmacies are separate facilities from clinical offices and physicians have no financial interests in pharmacies or pharmaceutical affairs. Physicians write a prescription, then patients are free to take the prescription to any pharmacy. Thus, in theory, pharmaceutical companies hardly influence health providers’ choices.

Notwithstanding, our study uncovered prescription shifts, which suggests that pharmaceutical companies reacted to the SPS with economic motives for profits. Pharmaceutical companies might have influenced health providers’ choices by replacing their reduced price products with other products outside of the range of the new pricing regulation. Of the 97 antidiabetic ingredients included in our analysis, eleven ingredients were introduced into the market just after the policy was introduced, and those eleven rapidly grew in cost by 20% per month between August 2012 and June 2013 based on our data. Pharmaceutical companies might have intensified marketing activities, which may have possibly affected healthcare providers’ prescription behavior towards constant price products. Meanwhile, the price difference between the reduced and the constant price products may not have been large enough for patients to stay with products with reduced prices when a healthcare provider suggested switching to a new one with a constant price.

Prescription shifts after the implementation of the SPS imply that the price cut for pharmaceuticals alone is not effective in controlling pharmaceutical expenditures in the long-run. Controlling pharmaceutical expenditures without sacrificing quality of care and adverse health outcomes requires other options such as additional cost control mechanisms on the demand side (i.e., tiered-benefit design, drug budget control [15], or more innovative programs such as value-based pricing).

To the best of our knowledge, this is the first study that measured the effects of the SPS on the cost and utilization of antidiabetic drugs and diabetic-induced medical and surgical procedure incidents through a rigorous quasi-experimental design. Unlike a previous study that examined the costs and utilization of antihypertensives with sample data that accounted for 1% of the Korean population [37], this study used the entire claims database. The Korean Diabetes Association [39] reported that the prevalence of diabetes was 10.1% in 2010, and about 3.2 million Koreans age 30 and above have diabetes. Another 3 million Koreans are at a prediabetic stage. Our cohort included about 4 million patients, which enclosed a comprehensive number of patients that was taking antidiabetics during the study period. In addition, different from Han et al. [36] that examined the impacts of the SPS on antibiotics during the nine months after policy implementation, we included data with a range of over a year, allowing us to control for seasonality factors, if any. Because pharmaceutical utilization can be seasonal, it is important to include data covering the whole year and test seasonality for the internal validity of the study [31].

However, there are some limitations to our study. We included claims from five major types of medical institutions (clinics, nursing homes, teaching hospitals, general hospitals, and other hospitals) and excluded those from dental hospitals/clinics, public healthcare centers, and herbal hospitals/clinics. Dental and herbal medical institutions were excluded because they were irrelevant in caring for diabetic patients. Public healthcare centers were excluded because they accounted for only a small portion of medical expenses, and healthcare providers were reimbursed in a different way from the institutions we examined. The five major types of medical institutions spent 81% of medical expenses for outpatient care in 2013 [28]. Thus, we expect that the excluded data may have limited the accuracy of our analysis but with only minor influence. We employed surrogate endpoints such as incidents of medical and surgical procedures to measure diabetic complications rather than examined clinical endpoints. This is an inherent limitation of the administrative claims data although we tried to include an exhaustive list of procedures related with diabetic complications. Patient level data investigation with clinical information will be necessary before concluding the effects of the SPS on public health.

Conclusions
A direct price cut policy, the Single Price System (SPS), contained costs in the Korean pharmaceutical market for antidiabetics for a short period by bringing an immediate
cost reduction in targeted pharmaceuticals. The saving was expected to be compensated by a prescription shift from reduced price pharmaceuticals to constant price pharmaceuticals in the long run. Trends of individual cost or utilization of antidiabetics were not significantly affected by the new policy. The effect of SPS was not evident to change rates of incidents of medical and surgical procedures. However, further research using clinical information is needed to conclude the clinical effect of SPS in patients with diabetes.

Abbreviations
antidiabetics_{p-cut}: Antidiabetics with reduced price; antidiabetics_{p-keep}: Antidiabetics with constant price; AR: 1st order Autocorrelation Maximum likelihood estimate; ATC: WHO Anatomic Therapeutic Chemical group; DDD: Defined daily dose; DW: Durbin-Watson d statistic; HIRA: Health Insurance Review & Assessment Service; ICD-10: 10th version of the International Classification of Diseases; KRW: Korean Won; MedAid: Medical Aid; NHI: National Health Insurance; OLS: Ordinary least squares estimate; OPPP: Outpatient Prescription Incentive Program; SD: Standard deviation; SPS: Single Price System

Acknowledgements
Data was provided by the Health Insurance Review and Assessment Service.

Ethical approval and consent to participate
This study received approval from the institutional review board of Pusan National University (PNU 2014–32-HR). The authors obtained all necessary administrative permission to access the data prior to conducting this study. Patient information was anonymized and de-identified by the Health Insurance Review and Assessment Service according to Korean privacy law.

Funding
This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (NRF-2016R1C1B1009198).

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions
HS and JK wrote the statistical analysis plan, analyzed data, and drafted the paper. IL was the principal investigator. She wrote the statistical analysis plan, analyzed and interpreted data, drafted and revised the paper. All authors read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1 College of Pharmacy, Pusan National University, Busan, South Korea. 2 Health Insurance Review & Assessment Service, Wonju, South Korea. 3 College of Pharmacy, Yeungnam University, 280 Daehak-ro, Gyeongsan, Gyeongbuk-do 38541, South Korea.

Received: 2 January 2018 Accepted: 29 May 2018 Published online: 08 June 2018

References
1. Guifin AM, Cabiedes L. Reforming pharmaceutical policies in the European Union: a ‘penguin effect’? Int J Health Serv. 2003;33(1):1–28.
2. Mossialos E, Mrazek M, Wallay T. Regulating pharmaceuticals in Europe: striving for efficiency, equity and quality. Maidenhead: Open University Press; 2004.
3. OECD. Pharmaceutical pricing policies in a global market. Paris: OECD (Organisation for Economic Co-operation and Development); 2008.
4. Traulsen JM, Almardottir AB. The argument for pharmaceutical policy. Pharm World Sci. 2005;27(1):7–12.
5. Maynard A, Blooor K. Dilemmas in regulation of the market for pharmaceuticals. Health Aff (Millwood). 2003;22(2):31–41.
6. Gray JAM. Doing the right things right. In: Evidence-based healthcare: how to make health policy and management decisions. 2nd ed. London: Harcourt Publishers Limited; 2001. p. 37–64.
7. Daniels N, Sabin J. The ethics of accountability in managed care reform. Health Aff. 1998;17(3):50–64.
8. Wharam JF, Daniels N. Toward evidence-based policy making and standardized assessment of health policy reform. JAMA. 2007;298(6):676–9.
9. Aaserud M, Dahlgren AT, Sturm H, Kosters JP, Hill S, Furbeg CD, Grill R, Henry DA, Osman AD, Ramsay C, et al. Pharmaceutical policies: effects on rational drug use, an overview of 13 reviews. (Protocol). Cochrane Db Syst Rev. 2006;2:CD004937.
10. Austvoll-Dahlgren A, Aaserud M, Vist G, Ramsay C, Oxman AD, Sturm H, Kosters JP, Vervry A. Pharmaceutical policies: effects of cap and co-payment on rational drug use. Cochrane Db Syst Rev. 2008;1:CD007017.
11. Green CJ, Madure M, Fortin PM, Ramsay CR, Aaserud M, Bardal S. Pharmaceutical policies: effects of restrictions on reimbursement. Cochrane Db Syst Rev. 2010;8:CD008654.
12. Jacobzone S. Pharmaceutical policies in OECD countries: reconciling social and industrial goals. Paris: Organisation for Economic Co-operation and Development; 2000.
13. Mrazek MF. Comparative approaches to pharmaceutical price regulation in the European Union. Croat Med J. 2002;43(4):453–61.
14. Mrazek M, Mossialos E, editors. Regulating pharmaceutical prices in the European Union. Maidenhead: Open University Press; 2004.
15. Lee H-I, Blooor K, Hewitt C, Maynard A. International experience in controlling pharmaceutical expenditure influencing patients and providers and regulating industry – a systematic review. J Health Serv Res Policy. 2015;20(1):52–9.
16. Thomson S, Mossialos E. Influencing demand for drugs through cost sharing. In: Mossialos E, Mrazek M, Wallay T, editors. Regulating pharmaceuticals in Europe: striving for efficiency, equity and quality. Maidenhead: Open University Press; 2004. p. 227–44.
17. Soumerai SB, Ross-Degnan D, Avorn J, Tj ML, Choodnovskiy I. Effects of Medicaid drug-payment limits on admission to hospitals and nursing homes. New Engl J Med. 1991;325(15):1072–7.
18. Tamblyn R, Laprise R, Hanley JA, Abrahamowicz M, Scott S, Mayo N, Hurley J, Grad R, Latimer E, Perreault R, et al. Adverse events associated with prescription drug cost-sharing among poor and elderly persons. JAMA. 2001;285(4):421–9.
19. Soumerai SB, McLaughlin TJ, Ross-Degnan D, Casteris CS, Bollini P. Effects of a limit on Medicaid drug-reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia. New Engl J Med. 1994;331(10):650–5.
20. Roblin DW, Platt R, Goodman MJ, Hsu J, Nelson WW, Smith DH, Andrade SE, Soumerai SB. Effect of increased cost-sharing on oral hypoglycemic use in five managed care organizations: how much is too much? Med Care. 2005;43(10):951–9.
21. Bloor K, Maynard A. International pharmaceutical policy: health creation or wealth creation? In: Freemantle N, Hill S, editors. Evaluating Pharmaceuticals for Health Policy and Reimbursement. London: BMJ; 2004.
22. Coulton L, Annemans L, Javier J, Brown R, Keskinan A. Risk-sharing mechanisms worldwide: a landscape analysis of health outcomes-based reimbursement agreements International Society for Pharmacoconomics and Outcomes Research. Phuket, 2010.
23. Adamski J, Godman B, Offer ska-Sujkovska G, Osnina B, Herholz H, Wendykovska K, Laius O, Jan S, Sermet C, Zara C, et al. Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers. BMC Health Serv Res. 2010;10:153.
24. Werthermeier AH, Huang M-T. The healthcare system and pharmaceutical prices in United States. In: Barbier Z-U-D, editor. Pharmaceutical prices in the 21st century. Switzerland: Springer International Publishing; 2015. p. 309–19.
25. Aaserud M, Dahlgren AT, Kosters JP, Osman AD, Ramsay C, Sturm H. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies. Cochrane Db Syst Rev. 2006;2:CD005979.
26. Acosta A, Ciapponi A, Aaserud M, Vietto V, Austvoll-Dahlgren A, Kosters JP, Vacca C, Machado M, Diaz Ayala DH, Oxman AD. Pharmaceutical policies: effects of prescription pricing, other pricing, and purchasing policies. Cochrane Db Syst Rev. 2006;2:CD005979.

Page 9 of 10
effects of reference pricing, other pricing, and purchasing policies. Cochrane Db Syst Rev. 2014;(10):CD005979.

27. Lee I-H, Blok K. Pharmaceutical pricing policies in South Korea. In: Babar Z-U-D, editor. Pharmaceutical prices in the 21st century. Switzerland: Springer International Publishing; 2015. p. 151–69.

28. NHIS, HIRA. National Health Insurance statistical yearbook 2013. National Health Insurance Service, Health Insurance Review & Assessment: Seoul; 2014.

29. Korean standard classification of diseases and causes of death. [http://www.koidc.or.kr/2016/kcd/v7.do#08n].

30. Health Insurance Review & Assessment Service. WHO ATC classification for prescription medications. Seoul: Health Insurance Review & Assessment Service; 2007.

31. Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D. Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther. 2002;27(4):299–309.

32. Ostrom CWJ. Time series regression analysis: nonlagged case. In: Time series analysis: regression techniques. 2nd ed. London: SAGE Publications, Inc.; 1990. p. 7–42.

33. Gujarati DN, Porter DC. Econometric modeling: model specification and diagnostic testing. In: Basic econometrics. Singapore: McGraw Hill; 2009. p. 467–522.

34. Social Pharmacy Committee in Korean Association of Pharmacy Education: Pharmaceuticals and National Health Insurance. In: Administrative and managerial pharmacy. Edited by Social Pharmacy Committee in Korean Association of Pharmacy Education. Seoul: PanMun Education; 2013. p. 107–145.

35. Kwon H-Y, Hong J-M, Godman B, Yang B-M. Price cuts and drug spending in South Korea: the case of antihyperlipidemic agents. Health Policy. 2013; 112(3):217–26.

36. Han E, Chae SM, Kim NS, Park S. Effects of pharmaceutical cost containment policies on doctors’ prescribing behavior: focus on antibiotics. Health Policy. 2015;119(9):1245–54.

37. Yoo KB, Lee SG, Park S, Kim TH, Ahn J, Cho MH, Park EC. Effects of drug price reduction and prescribing restrictions on expenditures and utilisation of antihypertensive drugs in Korea. BMJ Open. 2015;5(7):2014–006940.

38. Hsu JC, Lu CY, Wagner AK, Chan KA, Lai MS, Ross-Degnan D. Impacts of drug reimbursement reductions on utilization and expenditures of oral antidiabetic medications in Taiwan: an interrupted time series study. Health Policy. 2014;116(2–3):196–205.

39. Korean Diabetes Association. Diabetes fact sheet in Korea, vol. 2012. Seoul: Korean Diabetes Association, Korea Centers for Disease Control and Prevention.